Dissecting the heterogeneity of triple-negative breast cancer.

Auteurs : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Jaar : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pagina's : 1879-87

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Auteurs : Criscitiello C, Metzger-Filho O, Saini KS, de Castro G, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart M
Jaar : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pagina's : 209

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Auteurs : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pagina's : 612-22

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.

Auteurs : Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C, Cogliatti S, Hirchaud E, Ysebaert L, Bron D, Soulier J, Gaulard P, Houlgatte R, Gisselbrecht C, Thieblemont C
Jaar : 2012
Journal : Blood
Volume : 119(20)
Pagina's : 4619-24

Inflammation and Toll-like receptor ligation differentially affect the osteogenic potential of human mesenchymal stromal cells depending on their tissue origin.

Auteurs : Raicevic G, Najar M, Pieters K, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L
Jaar : 2012
Journal : Tissue Eng Part A
Volume : 18(13-14)
Pagina's : 1410-8

Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes.

Auteurs : Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L
Jaar : 2012
Journal : Immunol. Lett.
Volume : 146(1-2)
Pagina's : 50-6

Immune-Related Antigens, Surface Molecules and Regulatory Factors in Human-Derived Mesenchymal Stromal Cells: The Expression and Impact of Inflammatory Priming.

Auteurs : Najar M, Raicevic G, Kazan HF, De Bruyn C, Bron D, Toungouz M, Lagneaux L
Jaar : 2012
Journal : Stem Cell Rev
Volume : 8(4)
Pagina's : 1188-98

Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomised study by the European Lung Cancer Wo

Auteurs : Berghmans T, Lafitte JJ, Giner V, Berchier MC, Scherpereel A, Lewin D, Paesmans M, Meert AP, Bosschaerts T, Leclercq N, Sculier JP
Jaar : 2012
Journal : Lung Cancer
Volume : 77(3)
Pagina's : 605-610

Euthanasia: from ethical debate to clinical reality.

Auteurs : Berghmans T, Lossignol D
Jaar : 2012
Journal : Eur. Respir. J.
Volume : 40(4)
Pagina's : 804-5

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Auteurs : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Jaar : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pagina's : 465-74

Second primary cancers in head and neck cancer patients: a challenging entity.

Auteurs : de Castro G, Awada A
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 203-4

Clinical development of new formulations of cytotoxics in solid tumors.

Auteurs : Azim HA, Awada A
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 325-31

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Auteurs : Awada A, Vandone AM, Aftimos P
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 297-304

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Auteurs : Awada A, Bozovic-Spasojevic I, Chow L
Jaar : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pagina's : 494-504

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Auteurs : Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart-Gebhart M, Harbeck N
Jaar : 2012
Journal : Breast Cancer Res. Treat.
Volume : 134(3)
Pagina's : 1149-59

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Auteurs : Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L
Jaar : 2012
Journal : Breast
Volume : 21(4)
Pagina's : 507-13

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Auteurs : Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(9)
Pagina's : 897-905

Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives.

Auteurs : Akasbi Y, Awada A, Arifi S, Mellas N, El Mesbahi O
Jaar : 2012
Journal : Bull Cancer
Volume : 99(10)
Pagina's : 92-9

M-ficolin levels are associated with the occurrence of severe infections in patients with haematological cancer undergoing chemotherapy.

Auteurs : Ameye L, Paesmans M, Thiel S, Jensenius JC, Aoun M
Jaar : 2012
Journal : Clin. Exp. Immunol.
Volume : 167(2)
Pagina's : 303-8

Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome: a bicentric study.

Auteurs : Vaes M, Hites M, Cotton F, Bourguignon AM, Csergo M, Rasson C, Ameye L, Bron D, Jacobs F, Aoun M
Jaar : 2012
Journal : Antimicrob. Agents Chemother.
Volume : 56(12))
Pagina's : 6298-303